CordLife Opens Banking Facility in Hong Kong
The companies have initially invested US$1 million to develop this market. CordLife's lead facility in Singapore has been in operations for three years, and has been very successful in providing cord blood banking services in that market and in Southeast Asia, in support of current autologous stem cell therapy and transplantation needs. The new Hong Kong facility, in addition to the full range of cord blood processing and storage capabilities, is backed by a full sales and marketing team, and is expected to be the lead facility for North Asia.
Other news from the department manufacturing
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.